Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision: 63 days

Cancer Drug Resistance

Articles

Most Recent | Most Viewed | Most Downloaded

Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers

Open Access Review DOI: 10.20517/cdr.2024.81 26 Sep 2024
Views: Downloads:
Download PDF

Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy

Open Access Review DOI: 10.20517/cdr.2024.66 24 Sep 2024
Views: Downloads:
Download PDF

Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro

Open Access Original Article DOI: 10.20517/cdr.2024.50 20 Sep 2024
Views: Downloads:
Download PDF

Intercellular transfer of multidrug resistance mediated by extracellular vesicles

Open Access Review DOI: 10.20517/cdr.2024.84 20 Sep 2024
Views: Downloads:
Download PDF

Non-coding RNA and drug resistance in head and neck cancer

Open Access Review DOI: 10.20517/cdr.2024.59 19 Sep 2024
Views: Downloads:
Download PDF

Venetoclax resistance: mechanistic insights and future strategies

Open Access Review DOI: 10.20517/cdr.2021.125 5 May 2022
Views: Downloads:
Download PDF

Improving HER2 testing reproducibility in HER2-low breast cancer

Open Access Opinion DOI: 10.20517/cdr.2022.29 31 Aug 2022
Views: Downloads:
Download PDF

Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces

Open Access Review DOI: 10.20517/cdr.2022.20 1 Aug 2022
Views: Downloads:
Download PDF

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
We are excited to congratulate 25 Editorial Board members of the Cancer Drug Resistance (CDR) journal for being included in this prestigious ranking.
The journal Cancer Drug Resistance has established a media partnership with the European Association for Cancer Research (EACR) and Boehringer Ingelheim for the upcoming EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway.
We are pleased to announce that our journal, Cancer Drug Resistance (CDR), has obtained a new Impact Factor 2023 of 4.6, as reported by the Journal Citation Reports (JCR) released by Clarivate Analytics on June 20, 2024.
placing the journal in Q1 in the Pharmacology (medical) discipline
Their promotion recognizes their exceptional contributions to the journal and their steadfast dedication to advancing research in the field of cancer drug resistance.

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/